Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
(NASDAQ:REPL), WOBURN, Mass., June 06, 2025 (GLOBE NEWSWIRE) — Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the grant of inducement equity awards to newly hired non-executive employees. The Company granted equity awards to 10 employees as a material inducement to commencing their employment […]